Argenx Se (ARGX) Enterprise Value (2017 - 2026)
Argenx Se's (ARGX) quarterly Enterprise Value came in at -$5.2 billion in Q2 2026, up 99.55% YoY from -$2.6 billion in Q2 2025, and down 16.76% on a QoQ basis from -$4.4 billion in Q4 2025.
Analysis
Argenx Se (ARGX) Enterprise Value (2017 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Enterprise Value data on file, last reported at -$5.2 billion in Q2 2026.
- Quarterly Enterprise Value rose 99.55% year-over-year to -$5.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$5.2 billion (up 99.55% YoY) and the FY2025 annual result came in at -$5.9 billion, down 960.14% from the prior year.
- Enterprise Value slipped to -$5.2 billion in Q2 2026, from -$4.4 billion in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of $1107.0 billion in Q2 2024 to a low of -$1156.3 billion in Q2 2025.
- A 5-year average of -$8.0 billion and a median of -$3.2 billion in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 55532.62% — and 2025, when it plunged 204.46%.
- Tracing ARGX's Enterprise Value over 5 years: stood at -$2.2 billion in 2022, then slumped by 45.03% to -$3.2 billion in 2023, then fell by 6.26% to -$3.4 billion in 2024, then sank by 31.4% to -$4.4 billion in 2025, then fell by 16.76% to -$5.2 billion in 2026.
- The last three Enterprise Value figures came in at -$5.2 billion (Q2 2026), -$4.4 billion (Q4 2025), and -$1156.3 billion (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Incyte | 25.64 Bn | 21.11 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 52.23 Bn |
| Mar 31, 2026 | 45.19 Bn |
| Dec 31, 2025 | 47.60 Bn |
| Sep 30, 2025 | 44.81 Bn |
| Jun 30, 2025 | 30.25 Bn |
| Mar 31, 2025 | 35.96 Bn |
| Dec 31, 2024 | -1,843.02 Bn |
| Sep 30, 2024 | 32.09 Bn |
| Jun 30, 2024 | 1,132.43 Bn |
| Mar 31, 2024 | 23.31 Bn |
| Dec 31, 2023 | 19.34 Bn |
| Sep 30, 2023 | 27.23 Bn |
| Jun 30, 2023 | 19.59 Bn |
| Mar 31, 2023 | 20.64 Bn |
| Dec 31, 2022 | -1,371.62 Bn |
| Sep 30, 2022 | 18.24 Bn |
| Jun 30, 2022 | 16.98 Bn |
| Mar 31, 2022 | 16.29 Bn |
| Dec 31, 2021 | -985.29 Bn |
| Sep 30, 2021 | 14.37 Bn |